Oxygen Abundances in Two Metal-Poor Subgiants from the Analysis of the 6300 A Forbidden O I Line

Recent LTE analyses (Israelian et al. 1998 and Bosegaard et al. 1999) of the OH bands in the optical-ultraviolet spectra of nearby metal-poor subdwarfs indicate that oxygen abundances are generally higher than those previously determined. The difference increases with decreasing metallicity and reaches delta([O/Fe]) ~ +0.6 dex as [Fe/H] approaches -3.0. Employing high resolution (R = 50000), high S/N (~ 250) echelle spectra of the two stars found by Israelian et al. (1998) to have the highest [O/Fe]-ratios, viz, BD +23 3130 and BD +37 1458, we conducted abundance analyses based on about 60 Fe I and 7-9 Fe II lines. We determined from Kurucz LTE models the values of the stellar parameters, as well as abundances of Na, Ni, and the traditional alpha-elements, independent of the calibration of color vs $T_{eff}$ scales. We determined oxygen abundances from spectral synthesis of the stronger line (6300 A) of the [O I] doublet. The syntheses of the [O I] line lead to smaller values of [O/Fe], consistent with those found earlier among halo field and globular cluster giants. We obtain [O/Fe] = +0.35 +/- 0.2 for BD +23 3130 and +0.50 +/- 0.2 for BD +37 1458. In the former, the [O I] line is very weak (~ 1 mA), so that the quoted [O/Fe] value may in reality be an upper limit. Therefore in these two stars a discrepancy exists between the [O/Fe]- ratios derived from [O I] and the OH feature, and the origin of this difference remains unclear. Until the matter is clarified, we suggest it is premature to conclude that the ab initio oxygen abundances of old, metal-poor stars need to be revised drastically upward.Comment: 38 pages, 5 tables, 14 figures To appear in July 1999 AJ Updated April 16, 1999. Fixed typo

Mapping Vesta: First Results from Dawn’s Survey Orbit

The geologic objectives of the Dawn Mission [1] are to derive Vesta’s shape, map the surface geology, understand the geological context and contribute to the determination of the asteroids’ origin and evolution.Geomorphology and distribution of surface features will provide evidence for impact cratering, tectonic activity, volcanism, and regolith processes. Spectral measurements of the surface will provide evidence of the compositional characteristics of geological units. Age information, as derived from crater sizefrequency distributions, provides the stratigraphic context for the structural and compositional mapping results, thus revealing the geologic history of Vesta. We present here the first results of the Dawn mission from data collected during the approach to Vesta, and its first discrete orbit phase – the Survey Orbit, which lasts 21 days after the spacecraft had established a circular polar orbit at a radius of ~3000 km with a beta angle of 10°-15°

Complementary and conventional medicine: a concept map

BACKGROUND: Despite the substantive literature from survey research that has accumulated on complementary and alternative medicine (CAM) in the United States and elsewhere, very little research has been done to assess conceptual domains that CAM and conventional providers would emphasize in CAM survey studies. The objective of this study is to describe and interpret the results of concept mapping with conventional and CAM practitioners from a variety of backgrounds on the topic of CAM. METHODS: Concept mapping, including free sorts, ratings, and multidimensional scaling was used to organize conceptual domains relevant to CAM into a visual "cluster map." The panel consisted of CAM providers, conventional providers, and university faculty, and was convened to help formulate conceptual domains to guide the development of a CAM survey for use with United States military veterans. RESULTS: Eight conceptual clusters were identified: 1) Self-assessment, Self-care, and Quality of Life; 2) Health Status, Health Behaviors; 3) Self-assessment of Health; 4) Practical/Economic/ Environmental Concerns; 5) Needs Assessment; 6) CAM vs. Conventional Medicine; 7) Knowledge of CAM; and 8) Experience with CAM. The clusters suggest panelists saw interactions between CAM and conventional medicine as a critical component of the current medical landscape. CONCLUSIONS: Concept mapping provided insight into how CAM and conventional providers view the domain of health care, and was shown to be a useful tool in the formulation of CAM-related conceptual domains

A-type Supergiant Abundances in the SMC: Probes of Evolution

New abundances of N, O, Na, Mg, Si, Ca, Sc, Ti, Cr, Fe, Sr, Zr, and Ba are presented for 10 A-type supergiants in the SMC, plus upper limits for C. In interpreting the CNO results for constraints on stellar evolution theories, careful attention has been paid to the comparison abundances, i.e., the present day abundances of SMC nebulae and B-dwarf stars. These new results are also compared to published results from F-K supergiant analyses, and found to be in good agreement when both sets of data are carefully examined as differential (SMC minus Galactic standard) abundances. With the exception of nitrogen, very small star-to-star abundance variations are found for all elements in this analysis. The N variations are not predicted by standard stellar evolution models. Instead, the results support the new predictions reported from rotating stellar models, where the range in nitrogen is the result of partial mixing of CN-cycled gas from the stellar interior due to main-sequence rotation at different rates (c.f., Langer & Heger 1998). The overall overabundance of nitrogen in the sampled stars also implies these stars have undergone the first dredge-up in addition to having been mixed while on the main-sequence. The alpha-elements (O, Mg, Si, Ca, Ti) have similar underabundances to Fe, which is not the same as seen in metal-poor stars in the solar neighborhood of the Galaxy. In addition, certain light s-process elements (Zr, Ba) are slightly more underabundant than Fe, which is predicted by the bursting chemical evolution model presented by Pagel & Tautvaisiene (1998) for the SMC.Comment: Accepted for publication in the Astrophysical Journal, Manuscript #39295. Accepted January 4, 199

In Silico Insights into the Symbiotic Nitrogen Fixation in Sinorhizobium meliloti via Metabolic Reconstruction

BACKGROUND: Sinorhizobium meliloti is a soil bacterium, known for its capability to establish symbiotic nitrogen fixation (SNF) with leguminous plants such as alfalfa. S. meliloti 1021 is the most extensively studied strain to understand the mechanism of SNF and further to study the legume-microbe interaction. In order to provide insight into the metabolic characteristics underlying the SNF mechanism of S. meliloti 1021, there is an increasing demand to reconstruct a metabolic network for the stage of SNF in S. meliloti 1021. RESULTS: Through an iterative reconstruction process, a metabolic network during the stage of SNF in S. meliloti 1021 was presented, named as iHZ565, which accounts for 565 genes, 503 internal reactions, and 522 metabolites. Subjected to a novelly defined objective function, the in silico predicted flux distribution was highly consistent with the in vivo evidences reported previously, which proves the robustness of the model. Based on the model, refinement of genome annotation of S. meliloti 1021 was performed and 15 genes were re-annotated properly. There were 19.8% (112) of the 565 metabolic genes included in iHZ565 predicted to be essential for efficient SNF in bacteroids under the in silico microaerobic and nutrient sharing condition. CONCLUSIONS: As the first metabolic network during the stage of SNF in S. meliloti 1021, the manually curated model iHZ565 provides an overview of the major metabolic properties of the SNF bioprocess in S. meliloti 1021. The predicted SNF-required essential genes will facilitate understanding of the key functions in SNF and help identify key genes and design experiments for further validation. The model iHZ565 can be used as a knowledge-based framework for better understanding the symbiotic relationship between rhizobia and legumes, ultimately, uncovering the mechanism of nitrogen fixation in bacteroids and providing new strategies to efficiently improve biological nitrogen fixation

Studies of enzyme polymorphisms in the Kamuela population of Drosophila mercatorum . II. Evaluation of glycolytic intermediates

A simple and effective cryogenic procedure for the extraction of glycolytic intermediates from whole Drosophila has been developed. This procedure gives consistent results when a measure (µM/liter/OD 260 ) is adopted which corrects for differences in extraction efficiency. Using this measure and a homozygous strain of D. mercatorum , there are no significant differences among extracts for the levels of any of the 15 glycolytic intermediate or energy molecules considered. The profile of means is consistent across experimental designs and instrument types. Coefficients of variation are well below 50% for most variables. The methodology presented has the statistical power to detect a mean change of 10 to 50% using an experimental design which requires as few as 32 observations. The estimated energy charge for resting Drosophila from these studies is the expected value of 0.86.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44142/1/10528_2004_Article_BF00498934.pd

Status Update and Interim Results from the Asymptomatic Carotid Surgery Trial-2 (ACST-2)

Objectives: ACST-2 is currently the largest trial ever conducted to compare carotid artery stenting (CAS) with carotid endarterectomy (CEA) in patients with severe asymptomatic carotid stenosis requiring revascularization. Methods: Patients are entered into ACST-2 when revascularization is felt to be clearly indicated, when CEA and CAS are both possible, but where there is substantial uncertainty as to which is most appropriate. Trial surgeons and interventionalists are expected to use their usual techniques and CE-approved devices. We report baseline characteristics and blinded combined interim results for 30-day mortality and major morbidity for 986 patients in the ongoing trial up to September 2012. Results: A total of 986 patients (687 men, 299 women), mean age 68.7 years (SD ± 8.1) were randomized equally to CEA or CAS. Most (96%) had ipsilateral stenosis of 70-99% (median 80%) with contralateral stenoses of 50-99% in 30% and contralateral occlusion in 8%. Patients were on appropriate medical treatment. For 691 patients undergoing intervention with at least 1-month follow-up and Rankin scoring at 6 months for any stroke, the overall serious cardiovascular event rate of periprocedural (within 30 days) disabling stroke, fatal myocardial infarction, and death at 30 days was 1.0%. Conclusions: Early ACST-2 results suggest contemporary carotid intervention for asymptomatic stenosis has a low risk of serious morbidity and mortality, on par with other recent trials. The trial continues to recruit, to monitor periprocedural events and all types of stroke, aiming to randomize up to 5,000 patients to determine any differential outcomes between interventions. Clinical trial: ISRCTN21144362. © 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved

Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)

Despite widespread availability of a large body of evidence in the area of hypertension, the translation of that evidence into viable recommendations aimed at improving the quality of health care is very difficult, sometimes to the point of questionable acceptability and overall credibility of the guidelines advocating those recommendations. The scientific community world-wide and especially professionals interested in the topic of hypertension are witnessing currently an unprecedented debate over the issue of appropriateness of using different drugs/drug classes for the treatment of hypertension. An endless supply of recent and less recent "drug-news", some in support of, others against the current guidelines, justifying the use of selected types of drug treatment or criticising other, are coming out in the scientific literature on an almost weekly basis. The latest of such debate (at the time of writing this paper) pertains the safety profile of ARBs vs ACE inhibitors. To great extent, the factual situation has been fuelled by the new hypertension guidelines (different for USA, Europe, New Zeeland and UK) through, apparently small inconsistencies and conflicting messages, that might have generated substantial and perpetuating confusion among both prescribing physicians and their patients, regardless of their country of origin. The overwhelming message conveyed by most guidelines and opinion leaders is the widespread use of diuretics as first-line agents in all patients with blood pressure above a certain cut-off level and the increasingly aggressive approach towards diagnosis and treatment of hypertension. This, apparently well-justified, logical and easily comprehensible message is unfortunately miss-obeyed by most physicians, on both parts of the Atlantic. Amazingly, the message assumes a universal simplicity of both diagnosis and treatment of hypertension, while ignoring several hypertension-specific variables, commonly known to have high level of complexity, such as: - accuracy of recorded blood pressure and the great inter-observer variability, - diversity in the competency and training of diagnosing physician, - individual patient/disease profile with highly subjective preferences, - difficulty in reaching consensus among opinion leaders, - pharmaceutical industry's influence, and, nonetheless, - the large variability in the efficacy and safety of the antihypertensive drugs. The present 2-series article attempts to identify and review possible causes that might have, at least in part, generated the current healthcare anachronism (I); to highlight the current trend to account for the uncertainties related to the fixed blood pressure cut-off point and the possible solutions to improve accuracy of diagnosis and treatment of hypertension (II)

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0–1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0–2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4–6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10–2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05–1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06–2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4–6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52–1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03–4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22–25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None